Clinical trial
Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for…
NCT00110981 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00110981 |
|---|---|
| Title | Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis |
| Official title | A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis |
| Lead sponsor | Amgen, Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Device, Drug |
| Interventions | NB-UVB, Etanerept, Etanercept |
| Enrollment | 86 |
| Start date | Mar 1, 2005 |
| Primary completion | Feb 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | May 17, 2005 |
| Last update posted | May 24, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: